{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"AGEN 2034"},{"type":"CodeName","name":"AGEN2034"},{"type":"CodeName","name":"AGEN-2034"},{"type":"CASRegistryName","name":"2230167-06-1"}],"definition":{"html":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, balstilimab binds to PD-1, and thereby blocks its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","text":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, balstilimab binds to PD-1, and thereby blocks its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity."},"drugInfoSummaryLink":null,"nciConceptId":"C136465","nciConceptName":"Balstilimab","termId":789509,"name":"balstilimab","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"balstilimab"}],"links":null}